India's Alembic Pharma falls after brokerage warns of margin pressure

Alembic Pharmaceuticals

18/05/2026 05:48

** Shares of Alembic Pharmaceuticals ALEM.NS fall nearly 8.5% to 718.60 rupees

** Drugmaker's Q4 profit rose 29.2% y/y, helped by strong demand for its generic drugs, growth in U.S. business

** Total expenses jumped 8.8%; revenue from operations rose 4.4%

** Expenses were driven by R&D expenses, which rose 38.4% y/y

** ICICI Securities cuts PT by 80 rupees to 850 rupees; lowers FY27–FY28 earnings estimates by around 10-11% on margin pressure

** Estimates revenue and profit growing at 9.4% and 11.7% CAGR, respectively, over FY26–FY28

** ALEM closed down 0.2% after results on Friday

** YTD stock down about 11%

(Reporting by Bipasha Dey in Bengaluru)

((Bipasha.Dey@thomsonreuters.com;))